← 返回

基于机器学习的氧化磷酸化特征识别用于卵巢癌的预后、免疫浸润和药物敏感性

英文原题:Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer.

查看英文原题

Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer.

PubMed 2026/05/29(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究构建了一个新的 OC OPRGS。它可能作为预测 OC 患者预后、免疫浸润和化疗药物敏感性的潜在指标。

研究思路结论见上方概要

卵巢癌(OC)是一种高度异质性的疾病,其代谢特征也表现出异质性。然而,在OC代谢中起关键作用的具体代谢途径仍不清楚。此外,与这些代谢途径相关的基因在预后和治疗结局中的意义尚未明确。

本研究利用癌症基因组图谱计划(TCGA)、基因型-组织表达(GTEx)和多个基因表达综合数据库(GEO)数据集,对京都基因与基因组百科全书(KEGG)中的84条代谢通路进行了基因集富集分析(GSEA)。通过稳健秩聚合(RRA)分析,我们确定了变化最显著的代谢通路。利用与变化最显著的代谢通路相关的基因构建最稳健的机器学习模型,并结合单细胞测序分析结果,选择驱动蛋白家族成员1A(KIF1A)作为后续生物学水平研究的基因。

我们将氧化磷酸化(OXPHOS)确定为OC中的核心代谢通路之一。使用随机生存森林(RSF)和有监督主成分(SuperPC)方法构建了OXPHOS相关基因特征(OPRGS),其作为OC相对可靠的风险因素出现。在TCGA队列中,高风险评分患者表现出更高的ESTIMATE基质相关评分、与肿瘤相关成纤维细胞显著正相关、更高的肿瘤免疫功能障碍和排斥评分,以及更低的程序性细胞死亡蛋白-1(PD-1)和细胞毒性T淋巴细胞相关抗原-4(CTLA-4)免疫表型评分,提示基于生物信息学预测的免疫抑制性肿瘤微环境(TME)。此外,较高的OPRGS与较低的癌症干性指数、对紫杉醇耐药但对卡铂敏感相关,揭示了肿瘤复杂的生物学行为。进一步分析显示,高OPRGS还与癌症相关标志性信号通路的高评分相关,如Notch、血管生成和上皮-间充质转化信号通路。通过整合单细胞RNA测序数据,我们确定KIF1A为进一步研究的关键基因。我们的发现表明,KIF1A在OC细胞系中上调,并可能促进细胞增殖、侵袭和迁移。

展开英文摘要原文

Ovarian cancer (OC) is a highly heterogeneous disease, and its metabolic characteristics also exhibit heterogeneity. However, the specific metabolic pathways that play a critical role in OC metabolism remain unclear. Additionally, the significance of genes related to the metabolic pathways in the prognosis and therapeutic outcomes has not been clearly defined.

In this study, we utilized the Cancer Genome Atlas Program (TCGA), Genotype-Tissue Expression (GTEx), and multiple Gene Expression Omnibus (GEO) datasets to perform gene set enrichment analysis (GSEA) on 84 metabolic pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG). Through robust rank aggregation (RRA) analysis, we identified the most significantly altered metabolic pathways. By constructing the most robust machine learning model using genes related to the most significantly altered metabolic pathways and combining it with single-cell sequencing analysis results, kinesin family member 1A (KIF1A) was selected as the gene for subsequent biological level studies.

We identified oxidative phosphorylation (OXPHOS) as one of the core metabolic pathways in OC. The OXPHOS-related gene signature (OPRGS) was built using the random survival forest (RSF) and supervised principal components (SuperPC) methods, which emerges as a comparatively reliable risk factor for OC. Patients with high-risk scores exhibited higher ESTIMATE stromal-related scores, a significant positive correlation with tumor-associated fibroblasts, higher tumor immune dysfunction and exclusion scores, and lower programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) immunophenoscores in the TCGA cohort, suggesting an immunosuppressive tumor microenvironment (TME) based on bioinformatic predictions. Additionally, higher OPRGS was associated with lower cancer stemness indices, resistance to paclitaxel but sensitivity to carboplatin, revealing complex biological behaviors of the tumor. Further analysis showed that high OPRGS were also correlated with high scores in cancer-related hallmark signaling pathways, such as Notch, angiogenesis, and epithelial-mesenchymal transition signaling pathways. By integrating single-cell RNA sequencing data, we identified KIF1A as a key gene for further investigation. Our findings indicated that KIF1A was upregulated in OC cell lines and might promote cell proliferation, invasion, and migration.

This study constructed a new OPRGS for OC. It may serve as a potential indicator for predicting prognosis, immune infiltration, and chemotherapy drug sensitivity in OC patients.

论文信息

作者
Kang L、Yang Z、Ding Y、Wu Y、Ma C、Wang Y、Li C、Li B
单位
Department of Gynecology and Obstetrics, Clinical and Research Translation Center, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.China
期刊
Frontiers in immunology2026
原文标识
PubMed 42292348 · DOI 10.3389/fimmu.2026.1724930